Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Randomized Controlled Trial to Evaluate the Efficacy of Fluticasone Propionate MDI Added to Standard Care at Early Stage of COVID-19 in Reducing the Incidence of Adverse Outcomes in Symptomatic Patients Either From 18 to 49 Year Old With Risk Factors or Older Than 50 Year Old

NCT05054322 is registered in ClinicalTrials.gov with University of Medicine and Pharmacy at Ho Chi Minh City as lead sponsor.

NCT NCT05054322
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05054322 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Randomized Controlled Trial to Evaluate the Efficacy of Fluticasone Propionate MDI Added to Standard Care at Early Stage of COVID-19 in Reducing the Incidence of Adverse Outcomes in Symptomatic Patients Either From 18 to 49 Year Old With Risk Factors or Older Than 50 Year Old
Lead sponsor
University of Medicine and Pharmacy at Ho Chi Minh City
Phase
Phase 2/3
Overall status
Unknown status
Start date
September 22, 2021
Completion date
August 30, 2022
Enrollment
500 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid19